vs
FRIEDMAN INDUSTRIES INC（FRD）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是FRIEDMAN INDUSTRIES INC的1.3倍（$219.9M vs $168.0M），FRIEDMAN INDUSTRIES INC净利率更高（1.8% vs -1.0%，领先2.8%），FRIEDMAN INDUSTRIES INC同比增速更快（78.6% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-6.3M），过去两年FRIEDMAN INDUSTRIES INC的营收复合增速更高（13.3% vs 8.0%）
赫尔曼与弗里德曼（H&F）是一家美国私募股权公司，由沃伦·赫尔曼与塔利·弗里德曼于1984年创立，主要通过杠杆收购及成长资本开展投资业务，核心投资方向覆盖传媒、金融服务、专业服务与信息服务等多个领域。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FRD vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$168.0M
营收增速更快
FRD
高出76.6%
2.0%
净利率更高
FRD
高出2.8%
-1.0%
自由现金流更多
OFIX
多$23.2M
$-6.3M
两年增速更快
FRD
近两年复合增速
8.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.0M | $219.9M |
| 净利润 | $3.0M | $-2.2M |
| 毛利率 | 2.3% | 71.1% |
| 营业利润率 | 2.3% | 0.2% |
| 净利率 | 1.8% | -1.0% |
| 营收同比 | 78.6% | 2.0% |
| 净利润同比 | 364.1% | 92.4% |
| 每股收益（稀释后） | $0.43 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FRDOFIX
| Q4 25 | $168.0M | $219.9M | ||
| Q3 25 | $152.4M | $205.6M | ||
| Q2 25 | $134.8M | $203.1M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | $94.1M | $215.7M | ||
| Q3 24 | $106.8M | $196.6M | ||
| Q2 24 | $114.6M | $198.6M | ||
| Q1 24 | — | $188.6M |
净利润FRDOFIX
| Q4 25 | $3.0M | $-2.2M | ||
| Q3 25 | $2.2M | $-22.8M | ||
| Q2 25 | $5.0M | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | $-1.2M | $-29.1M | ||
| Q3 24 | $-675.0K | $-27.4M | ||
| Q2 24 | $2.6M | $-33.4M | ||
| Q1 24 | — | $-36.0M |
毛利率FRDOFIX
| Q4 25 | 2.3% | 71.1% | ||
| Q3 25 | 1.9% | 72.2% | ||
| Q2 25 | 5.2% | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | -0.2% | 68.7% | ||
| Q2 24 | -1.2% | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率FRDOFIX
| Q4 25 | 2.3% | 0.2% | ||
| Q3 25 | 1.9% | -8.3% | ||
| Q2 25 | 5.2% | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | -1.3% | -5.3% | ||
| Q3 24 | -0.2% | -9.6% | ||
| Q2 24 | -1.2% | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率FRDOFIX
| Q4 25 | 1.8% | -1.0% | ||
| Q3 25 | 1.5% | -11.1% | ||
| Q2 25 | 3.7% | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | -1.2% | -13.5% | ||
| Q3 24 | -0.6% | -13.9% | ||
| Q2 24 | 2.2% | -16.8% | ||
| Q1 24 | — | -19.1% |
每股收益（稀释后）FRDOFIX
| Q4 25 | $0.43 | $-0.05 | ||
| Q3 25 | $0.32 | $-0.57 | ||
| Q2 25 | $0.71 | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | $-0.17 | $-0.76 | ||
| Q3 24 | $-0.10 | $-0.71 | ||
| Q2 24 | $0.37 | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $142.2M | $450.0M |
| 总资产 | $311.9M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FRDOFIX
| Q4 25 | $3.0M | $82.0M | ||
| Q3 25 | $4.6M | $62.9M | ||
| Q2 25 | $2.1M | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | $1.1M | $83.2M | ||
| Q3 24 | $2.5M | $30.1M | ||
| Q2 24 | $4.1M | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务FRDOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益FRDOFIX
| Q4 25 | $142.2M | $450.0M | ||
| Q3 25 | $139.3M | $442.5M | ||
| Q2 25 | $137.3M | $458.3M | ||
| Q1 25 | — | $458.3M | ||
| Q4 24 | $127.3M | $503.1M | ||
| Q3 24 | $128.8M | $525.9M | ||
| Q2 24 | $129.7M | $546.0M | ||
| Q1 24 | — | $570.3M |
总资产FRDOFIX
| Q4 25 | $311.9M | $850.6M | ||
| Q3 25 | $311.3M | $832.6M | ||
| Q2 25 | $219.1M | $837.2M | ||
| Q1 25 | — | $823.1M | ||
| Q4 24 | $210.3M | $893.3M | ||
| Q3 24 | $209.2M | $867.9M | ||
| Q2 24 | $222.8M | $882.0M | ||
| Q1 24 | — | $906.0M |
负债/权益比FRDOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.7M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-6.3M | $16.8M |
| 自由现金流率自由现金流/营收 | -3.8% | 7.6% |
| 资本支出强度资本支出/营收 | 1.0% | 4.9% |
| 现金转化率经营现金流/净利润 | -1.56× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FRDOFIX
| Q4 25 | $-4.7M | $27.7M | ||
| Q3 25 | $434.0K | $12.4M | ||
| Q2 25 | $15.5M | $11.6M | ||
| Q1 25 | — | $-18.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | $-6.1M | $9.0M | ||
| Q1 24 | — | $-18.6M |
自由现金流FRDOFIX
| Q4 25 | $-6.3M | $16.8M | ||
| Q3 25 | $-2.0M | $2.5M | ||
| Q2 25 | $13.7M | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | $-7.1M | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率FRDOFIX
| Q4 25 | -3.8% | 7.6% | ||
| Q3 25 | -1.3% | 1.2% | ||
| Q2 25 | 10.2% | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | -6.2% | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度FRDOFIX
| Q4 25 | 1.0% | 4.9% | ||
| Q3 25 | 1.6% | 4.8% | ||
| Q2 25 | 1.3% | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | 0.9% | 4.7% | ||
| Q1 24 | — | 5.6% |
现金转化率FRDOFIX
| Q4 25 | -1.56× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 3.08× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.36× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRD
| Prime Coil | $152.0M | 90% |
| Manufactured Pipe | $14.9M | 9% |
| Customer Owned | $1.1M | 1% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
